MyFinsight
Home
Blog
About
Net proceeds from
issuance of series c...
$6,182,447
Net proceeds from
warrant exercise
$1,046,760
Proceeds from investment
note receivable
$5,000,000
Net cash provided by
(used in) financing...
$6,581,577
(126.30%↑ Y/Y)
Net cash provided by
(used in) investing...
$2,000,000
(128.57%↑ Y/Y)
Effect of currency rate
exchange on cash and cash...
$3,073
(958.38%↑ Y/Y)
Canceled cashflow
$647,630
Canceled cashflow
$3,000,000
Net increase
(decrease) in cash and cash...
$3,431,736
(109.80%↑ Y/Y)
Canceled cashflow
$5,152,914
Repurchase of common stock,
net
$401,625
(-84.20%↓ Y/Y)
Payment of series c
convertible preferred stock...
$246,005
Change in fair value of
investment - qcls
-$7,732,000
Change in fair value of
warrant liability
-$4,746,135
(-145.43%↓ Y/Y)
Change in fair value of
warrant assets - femasys
-$2,581,000
(-23.43%↓ Y/Y)
Intangible asset
impairment
$1,549,427
Change in fair value of
warrants - qcls
-$1,379,000
Issuance costs series c
preferred stock and...
$1,234,553
Stock issued for
compensation - rsus
$892,500
(86.47%↑ Y/Y)
Unrealized (gain) loss on
marketable equity...
-$412,306
(-721.73%↓ Y/Y)
Stock-based compensation -
options
$236,056
Loss on issuance of
series c preferred...
$215,000
Investment in preferred
stock and warrants -...
$3,000,000
Net cash used in
operating activities
-$5,152,914
(-73.02%↓ Y/Y)
Canceled cashflow
$20,977,977
Net income (loss)
-$19,424,654
(-163.36%↓ Y/Y)
Gain on related party
investment - qcls
$2,089,000
Increase (decrease) in
accrued expenses
-$1,548,249
(-218.15%↓ Y/Y)
Change in fair value of
convertible note receivable...
$1,304,000
(38.58%↑ Y/Y)
Change in fair value of
derivative liability
$1,117,000
(-48.86%↓ Y/Y)
(increase) decrease in
prepaid expenses and...
$251,386
(797.50%↑ Y/Y)
Non-cash interest income
$162,500
(-45.83%↓ Y/Y)
Increase (decrease) in
accounts payable
-$128,102
(-1402.51%↓ Y/Y)
Gain on re-fair value
of warrants
$106,000
Back
Back
Cash Flow
PharmaCyte Biotech, Inc. (PMCB)
PharmaCyte Biotech, Inc. (PMCB)
source: myfinsight.com